|
| 38039779 | First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. | Eur J Cancer | 2024 |
| 38039779 | First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. | Eur J Cancer | 2024 |
| 37839734 | Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. | J Am Acad Dermatol | 2024 |
| 37861398 | Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy. | Clin Cancer Res | 2024 |
| 37861398 | Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy. | Clin Cancer Res | 2024 |
| 37839734 | Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. | J Am Acad Dermatol | 2024 |
| 36049147 | Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. | J Clin Oncol | 2023 |
| 36049147 | Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. | J Clin Oncol | 2023 |
| 36282874 | Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. | Clin Cancer Res | 2023 |
| 36137524 | Swiss Recommendations for Cutaneous Basal Cell Carcinoma. | Dermatology | 2023 |
| 35998300 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. | J Clin Oncol | 2023 |
| 36437681 | Tenascin C is a valuable marker for melanoma progression independent of mutational status and MAPK inhibitor therapy. | Exp Dermatol | 2023 |
| 36433688 | Real-world outcomes using PD-1 antibodies and BRAFÂ +â¿¿MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. | J Eur Acad Dermatol Venereol | 2023 |
| 37604067 | European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. | Eur J Cancer | 2023 |
| 37747367 | Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma. | Oncotarget | 2023 |
| 37594336 | Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. | Eur J Dermatol | 2023 |
| 37728439 | Immune-Related Sclerosing Cholangitis and Subsequent Pyogenic Liver Abscesses in Two Patients With Melanoma Treated by Triplet Therapy: A Case Report. | J Immunother | 2023 |
| 37904969 | The genetic evolution of acral melanoma. | bioRxiv | 2023 |
| 37807968 | NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5. | EMBO Mol Med | 2023 |
| 37717283 | European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023. | Eur J Cancer | 2023 |
| 37568633 | Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma. | Cancers (Basel) | 2023 |
| 37890355 | EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023. | Eur J Cancer | 2023 |
| 37880788 | The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. | J Transl Med | 2023 |
| 37708630 | European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023. | Eur J Cancer | 2023 |
| 37561473 | Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37874473 | What Is New in Cutaneous T Cell Lymphoma? | Curr Oncol Rep | 2023 |
| 37870955 | Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. | N Engl J Med | 2023 |
| 37474523 | Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. | Nat Commun | 2023 |
| 37089863 | Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence. | Cancer Res Commun | 2023 |
| 37338842 | mRNA-COVID-19-Impfstoff-induzierte Recall-Dermatitis nach topischem Imiquimod. | J Dtsch Dermatol Ges | 2023 |
| 37149545 | Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma. | Ann Surg Oncol | 2023 |
| 37021424 | Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge? | ESC Heart Fail | 2023 |
| 36765834 | P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma. | Cancers (Basel) | 2023 |
| 37459873 | Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. | Lancet Oncol | 2023 |
| 37459871 | Retraction and republication-TRICOTEL: defining symptomatic brain metastases in clinical trials. | Lancet Oncol | 2023 |
| 36638181 | Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma. | Sci Adv | 2023 |
| 37193799 | Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. | Nat Med | 2023 |
| 37066611 | mRNA COVID 19 vaccine-induced recall dermatitis after topical imiquimod. | J Dtsch Dermatol Ges | 2023 |
| 37444540 | Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study. | Cancers (Basel) | 2023 |
| 37442495 | Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. | Crit Rev Oncol Hematol | 2023 |
| 36693381 | Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. | Med | 2023 |
| 37309702 | COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. | Future Oncol | 2023 |
| 37119050 | Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors. | Cancer Med | 2023 |
| 37307514 | First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. | J Clin Oncol | 2023 |
| 36988735 | Chemotherapy in Cutaneous Melanoma: Is There Still a Role? | Curr Oncol Rep | 2023 |
| 36980709 | Recent Progress in the Diagnosis and Treatment of Melanoma and Other Skin Cancers. | Cancers (Basel) | 2023 |
| 37513847 | Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis. | Pharmaceuticals (Basel) | 2023 |
| 37506329 | Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. | J Clin Oncol | 2023 |
| 37487833 | EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. | J Am Acad Dermatol | 2023 |
| 36914141 | Phase-specific signatures of wound fibroblasts and matrix patterns define cancer-associated fibroblast subtypes. | Matrix Biol | 2023 |